相关实验视频

Updated: Jul 13, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

在细胞癌中对免疫检查点抑制剂失去反应的新兴抵抗:两个不同的现象

Arya Mariam Roy¹, Saby George¹

¹Division of Hematology and Oncology, Department of Internal Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.

Cancer drug resistance (Alhambra, Calif.)

|October 16, 2023

概括

免疫检查点抑制剂 (ICI) 已经改变了转移性细胞癌 (mRCC) 的治疗方法. 本综述探讨了抗药性机制和改善ICI治疗患者治疗结果的策略.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
医学研究医学研究

背景情况:

免疫检查点抑制剂 (ICI) 已经彻底改变了转移性细胞癌 (mRCC) 治疗,显著改善了患者的生存率.
结合ICI和其他疗法,进一步改善了mRCC患者的治疗结果.

研究的目的:

审查mRCC中对ICI治疗的原发性和获得性耐药性的机制.
为了确定个性化治疗策略的潜在生物标志物.
探索新的治疗方法来克服ICI耐药性.

主要方法:

文献综述总结了关于mRCC中ICI耐药性的当前研究.
分析机制,包括瘤微环境变化,替代免疫检查点和遗传/表观遗传变化.
识别新出现的克服阻力策略.

主要成果:

尽管ICI有效,但mRCC患者的一个子集表现出初级或获得性耐药性.
关键的抵抗机制包括瘤微环境,替代性免疫检查点和遗传/表观遗传变化.
需要新的预测生物标志物和治疗策略来进行个性化mRCC治疗.

结论:

了解ICI抵抗机制对于推进mRCC管理至关重要.
组合疗法,向药物和免疫调节在克服抵抗方面显示出有前途.
预测生物标志物的开发对于优化mRCC的ICI治疗至关重要.

关键词:

细胞癌是细胞癌.获得的电阻获得的电阻免疫检查点抑制剂免疫检查点抑制剂免疫疲标志物免疫疲标志物免疫抑制瘤微环境免疫抑制瘤微环境免疫疗法免疫疗法主要电阻的主要电阻.

更多相关视频

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...